These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25070543)

  • 41. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.
    Kappetein AP; Head SJ; Généreux P; Piazza N; van Mieghem NM; Blackstone EH; Brott TG; Cohen DJ; Cutlip DE; van Es GA; Hahn RT; Kirtane AJ; Krucoff MW; Kodali S; Mack MJ; Mehran R; Rodés-Cabau J; Vranckx P; Webb JG; Windecker S; Serruys PW; Leon MB;
    J Thorac Cardiovasc Surg; 2013 Jan; 145(1):6-23. PubMed ID: 23084102
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation.
    Mercieca-Bebber RL; Perreca A; King M; Macann A; Whale K; Soldati S; Jacobs M; Efficace F
    Eur J Cancer; 2016 Mar; 56():144-161. PubMed ID: 26851406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop.
    Tong A; Manns B; Wang AYM; Hemmelgarn B; Wheeler DC; Gill J; Tugwell P; Pecoits-Filho R; Crowe S; Harris T; Van Biesen W; Winkelmayer WC; Levin A; Thompson A; Perkovic V; Ju A; Gutman T; Bernier-Jean A; Viecelli AK; O'Lone E; Shen J; Josephson MA; Cho Y; Johnson DW; Sautenet B; Tonelli M; Craig JC;
    Kidney Int; 2018 Dec; 94(6):1053-1068. PubMed ID: 30360959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.
    Demetri GD; Benjamin R; Blanke CD; Choi H; Corless C; DeMatteo RP; Eisenberg BL; Fletcher CD; Maki RG; Rubin BP; Van den Abbeele AD; von Mehren M;
    J Natl Compr Canc Netw; 2004 May; 2 Suppl 1():S-1-26; quiz 27-30. PubMed ID: 23573667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
    Gourgou-Bourgade S; Cameron D; Poortmans P; Asselain B; Azria D; Cardoso F; A'Hern R; Bliss J; Bogaerts J; Bonnefoi H; Brain E; Cardoso MJ; Chibaudel B; Coleman R; Cufer T; Dal Lago L; Dalenc F; De Azambuja E; Debled M; Delaloge S; Filleron T; Gligorov J; Gutowski M; Jacot W; Kirkove C; MacGrogan G; Michiels S; Negreiros I; Offersen BV; Penault Llorca F; Pruneri G; Roche H; Russell NS; Schmitt F; Servent V; Thürlimann B; Untch M; van der Hage JA; van Tienhoven G; Wildiers H; Yarnold J; Bonnetain F; Mathoulin-Pélissier S; Bellera C; Dabakuyo-Yonli TS
    Ann Oncol; 2015 Dec; 26(12):2505-6. PubMed ID: 26467471
    [No Abstract]   [Full Text] [Related]  

  • 47. Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor.
    Kondo T; Suehara Y; Kikuta K; Kubota D; Tajima T; Mukaihara K; Ichikawa H; Kawai A
    Proteomics Clin Appl; 2013 Jan; 7(1-2):70-8. PubMed ID: 23281253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Core Outcome Set for GROwth restriction: deVeloping Endpoints (COSGROVE).
    Healy P; Gordijn S; Ganzevoort W; Beune I; Baschat A; Khalil A; Kenny L; Bloomfield F; Daly M; Papageorghiou A; Devane D
    Trials; 2018 Aug; 19(1):451. PubMed ID: 30134949
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surrogate Endpoints in Localized Prostate Cancer.
    Hartman HE; Jackson WC
    Cancer J; 2020; 26(1):48-52. PubMed ID: 31977385
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
    JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical guidelines for the management of gastrointestinal stromal tumors].
    Lopez M; Comandone A; Adamo V; Apice G; Bearzi I; Bracci R; Carlini M; Carpano S; Condorelli S; Covello R; Cucchiara G; Di Filippo F; Doglietto GB; Ficorella C; Garofalo A; Gebbia N; Giuliani F; Massidda B; Messerini L; Palmirotta R; Tonelli F; Vidiri A
    Clin Ter; 2006; 157(3):283-99. PubMed ID: 16900856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
    Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M
    Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes for Pressure Ulcer Trials (OUTPUTs): protocol for the development of a core domain set for trials evaluating the clinical efficacy or effectiveness of pressure ulcer prevention interventions.
    Lechner A; Kottner J; Coleman S; Muir D; Bagley H; Beeckman D; Chaboyer W; Cuddigan J; Moore Z; Rutherford C; Schmitt J; Nixon J; Balzer K
    Trials; 2019 Jul; 20(1):449. PubMed ID: 31331366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials.
    Wong SE; Quinn DI; Bjarnason GA; North SA; Sridhar SS
    Am J Clin Oncol; 2020 Aug; 43(8):559-566. PubMed ID: 32398404
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes in the management of adult soft tissue sarcomas.
    Kneisl JS; Coleman MM; Raut CP
    J Surg Oncol; 2014 Oct; 110(5):527-38. PubMed ID: 24965077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Diagnosis and therapy of GIST].
    Helmberger T
    Radiologe; 2009 Dec; 49(12):1103. PubMed ID: 20012259
    [No Abstract]   [Full Text] [Related]  

  • 57. Sample size implications of mortality definitions in sepsis: a retrospective cohort study.
    Govindan S; Prescott HC; Chopra V; Iwashyna TJ
    Trials; 2018 Mar; 19(1):198. PubMed ID: 29587803
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What is changing in the surgical treatment of gastrointestinal stromal tumors after multidisciplinary approach? A comprehensive literature's review.
    DE Simone B; Ansaloni L; Sartelli M; Coccolini F; DI Saverio S; Pantaleo MA; Saponara M; Nannini M; Abongwa HK; Napoli JA; Catena F
    Minerva Chir; 2017 Jun; 72(3):219-236. PubMed ID: 28198176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine initiative: patient-centred outcomes.
    Moonesinghe SR; Jackson AIR; Boney O; Stevenson N; Chan MTV; Cook TM; Lane-Fall M; Kalkman C; Neuman MD; Nilsson U; Shulman M; Myles PS;
    Br J Anaesth; 2019 Nov; 123(5):664-670. PubMed ID: 31493848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.